Avastin Plus Commonly Used Chemotherapies Improved Progression-Free Survival In Women With Previously Treated Advanced Breast Cancer

SOUTH SAN FRANCISCO, Calif. -- Genentech, Inc., a wholly-owned member of the Roche Group, today announced that a Phase III study (RIBBON 2) of Avastin(R) (bevacizumab) in combination with chemotherapy increased the time women with metastatic HER2-negative breast cancer whose initial chemotherapy had stopped working lived without the disease worsening (progression-free survival or PFS), compared to chemotherapy alone. The doctors treating the women in the study chose the type of chemotherapy used in combination with Avastin and the chemotherapies were assessed together in the primary endpoint analysis. Adverse events were consistent with those previously reported for Avastin, and no new Avastin safety signals were observe...